U.S. Semiconductors Stock News

SuperCom Ltd. ( NASDAQ:SPCB ), is not the largest company out there, but it saw significant share price movement during...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...

Those holding Sify Technologies Limited ( NASDAQ:SIFY ) shares would be relieved that the share price has rebounded 32...

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...

Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...

One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...

We wouldn't blame Sempra ( NYSE:SRE ) shareholders if they were a little worried about the fact that Jeffrey Martin...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...

It's nice to see the DHI Group, Inc. ( NYSE:DHX ) share price up 10% in a week. But that is small recompense for the...

If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly...

Those holding Insperity, Inc. ( NYSE:NSP ) shares would be relieved that the share price has rebounded 28% in the last...

If you are wondering whether Canadian Solar at around US$19.39 is a bargain or a value trap, you are not alone, especially after a volatile few years for solar stocks. The share price has fallen 18.4% over the last 7 days and 15.9% over the last 30 days, yet it is still showing a 52.2% gain over the last year after much weaker 3 and 5 year returns of 55.1% and 65.1% declines. Recent price moves sit against an ongoing global focus on renewable energy and policy support for solar projects...

Hyperscale Data (GPUS) is back in focus after releasing preliminary year end asset estimates, detailing a Bitcoin treasury that now exceeds its market capitalization and pledging more frequent balance sheet updates through 2026. See our latest analysis for Hyperscale Data. The latest balance sheet update and Bitcoin focus come after a volatile period, with a 93.68% 7 day share price return and a 30.26% year to date share price return, set against a 1 year total shareholder return of...

Arcutis Biotherapeutics (ARQT) has drawn fresh investor attention after reporting strong revenue growth tied to its dermatology pipeline, with lead product ZORYVE playing a central role even as the company continues to post operating losses. See our latest analysis for Arcutis Biotherapeutics. The recent dermatology update comes after a strong 90 day share price return of 49.03% and a 1 year total shareholder return of 95.68%. This suggests momentum has been building around Arcutis...

Immuneering (IMRX) is back on traders’ screens after releasing updated Phase 2a data for atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer, showing higher overall survival and response metrics than standard benchmarks. See our latest analysis for Immuneering. The updated atebimetinib data arrive after a tough recent stretch, with the share price at US$4.73 and a 1 day share price return of 43.22% decline. However, a 1 year total shareholder return of 136.5%...

If you are wondering whether Comerica's share price still offers value after a strong run, this review will help you separate sentiment from what the numbers suggest. Comerica's stock last closed at US$92.56, with returns of 6.5% over 7 days, 10.5% over 30 days, 4.4% year to date, 55.1% over 1 year, 57.3% over 3 years and 76.8% over 5 years. Recent market attention on U.S. regional banks has kept Comerica in focus, as investors reassess how interest rate expectations and credit conditions...

Why TaskUs Stock Is Back on Investors’ Radar TaskUs (TASK) has attracted fresh attention after recent performance data highlighted mixed returns across different timeframes, prompting investors to reassess the outsourcing specialist’s valuation and business momentum. See our latest analysis for TaskUs. Recent trading has been steady rather than dramatic, with a modest 1-day share price return of 1.11% and year to date share price return of 3.85%. This is set against a weaker 1-year total...

If you are wondering whether RadNet's recent share price puts it "on sale" or already pricing in a lot of optimism, you are in the right place. RadNet closed at US$78.38, with returns of 9.9% over the last 7 days, 3.3% over 30 days, 10.5% year to date, 8.5% over 1 year, and a very large gain over 3 years that is close to 3x, plus 273.2% over 5 years. Recent coverage around RadNet has focused on the business more broadly, giving investors extra context for the current share price and those...

MSC Industrial Direct (MSM) opened fiscal Q1 2026 with total revenue of US$965.7 million and basic EPS of US$0.93, alongside net income excluding extra items of US$51.8 million, providing an updated view of how its margins are holding up. Over recent quarters, the company has reported revenue of US$952.3 million in Q4 2024, US$928.5 million in Q1 2025, and US$965.7 million in Q1 2026. EPS over the same periods was US$0.99, then US$0.83, and now US$0.93, which puts the latest results in...

Some investors are considering whether Toro's current share price aligns with its underlying worth, or if recent market interest has pushed it away from that level. Toro's stock has recently traded at US$87.87, with returns of 11.6% over the last 7 days, 26.1% over 30 days, 9.6% year to date, 13.2% over 1 year, but declines of 20.0% over 3 years and 5.3% over 5 years. Recent attention on Toro has focused on how its long-term share performance compares with shorter-term gains, which has put...

Viridian Therapeutics (VRDN) is in focus after the FDA accepted its Biologics License Application for veligrotug in thyroid eye disease under Priority Review, while multiple late stage programs and pipeline updates continue to attract investor attention. See our latest analysis for Viridian Therapeutics. Despite a softer patch recently, with a 30 day share price return of 4.62% and a 7 day share price return of 2.54%, Viridian’s 90 day share price return of 44.50% and 1 year total shareholder...

If you are wondering whether Cincinnati Financial's current share price reflects its true worth, you are not alone. That is exactly what this article is set up to unpack. The stock last closed at US$165.19, with returns of 1.1% over 7 days, 2.3% over 30 days, 2.3% year to date, 19.3% over 1 year, 65.3% over 3 years and 99.9% over 5 years, which gives useful context before looking at what the valuation suggests. Recent coverage around the insurance sector more broadly has kept investor...

Constellation Brands (STZ) has just posted Q3 2026 results with revenue of US$2,222.8 million and basic EPS of US$2.88, while trailing twelve month revenue came in at US$9.4 billion and EPS at US$6.27. Over recent quarters, revenue has ranged from US$2,164.2 million in Q4 2025 to US$2,515 million in Q1 2026, with basic EPS moving from a loss of US$2.09 in Q4 2025 to positive readings between US$2.65 and US$2.90 across 2026 so far. This sets up the latest quarter against a backdrop of shifting...